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In many research studies, tobacco users are asked to forgo tobacco 
during study appointments to avoid interrupting study sessions with 
breaks or disrupting research flow and efficiency. Although onset of 
withdrawal varies according to levels of nicotine dependence, symp-
toms commonly begin within 30 minutes of abstinence.1 Symptoms 
of nicotine withdrawal include irritability, restlessness, anxiety, and 
difficulty concentrating.2 Nicotine cravings pose a particular problem 
in tobacco research, as discussion of tobacco products and tasks par-
ticipants complete may act as triggers to use.3 In recent focus groups 
among adults that currently smoke cigarettes, we offered nicotine 
replacement therapy (NRT) to participants to prevent nicotine with-
drawal and encourage participants to stay in the 90-minute session. To 
our knowledge, no previous research has undertaken this approach. 
This letter documents the use and perceptions of NRT in our focus 
groups, and makes recommendations based on our experience.
NRT can reduce the desire to use cigarettes and ameliorate with-
drawal symptoms experienced during quit attempts.4 While NRT is 
most commonly used to aid in smoking cessation, research shows that 
NRT is safe to use regardless of quit intentions, and that certain prod-
ucts can be used on demand to combat acute nicotine cravings.5 NRT 
is supported by the World Health Organization (WHO) Framework 
Convention on Tobacco Control and was added to the WHO Model 
List of Essential Medicines in 2009.6,7 NRT products are available 
in most countries, although accessibility is limited in many develop-
ing countries.8 In the United States NRT can be purchased over the 
counter in the form of a patch, gum or a lozenge. The nicotine lozenge 
is especially effective for curbing acute tobacco cravings, as it allows 
the user to control the timing and dosage for rapid release of nicotine.
As part of a larger study on tobacco control communication, 
we conducted five focus groups with adults who currently smoke 
cigarettes. The 90-minute sessions had no planned breaks so that 
the flow of discussion was not interrupted. We provided 2 mg nico-
tine lozenges that participants could use at any time. Lozenges were 
placed in the middle of the table with brief instructions for use, and 
participants were free to utilize them at any time during the study 
session.
Four of 51 participants utilized the nicotine lozenges, and reac-
tions to the available NRT were overwhelmingly positive. Participants 
reported that the NRT provision helped avoid potential nicotine crav-
ings and was a nice and respectful gesture. Typical comments included:
“Yeah, it’s like a nice gesture.”
“. . . it was extremely thoughtful because that’s a good reason for 
us not to get up. . . ”
“. . . it helps keep you calm, because we’re all smokers, so I think 
you definitely should keep offering those.”
Participants offered suggestions to more effectively provide NRT in 
future research settings, indicating they would feel more comfortable 
if the products were passed around the table or placed at each seat in 
order to minimize the attention drawn to those who chose to utilize 
the products. Participants explained:
“I think it would be better if you gave everyone like one.”
“. . . so it’s not, like, awkward.”
Some participants’ lack of familiarity with NRT kept them from 
using the lozenges. Although the facilitators began each group with 
a short introduction, more in-depth instructions on the NRT prod-
uct would be helpful to ensure that participants understand product 
function and purpose. Participants also suggested providing regular 
mints or gum for those who do not wish to utilize NRT.
The positive feedback we received from participants and the ease of 
use of NRT in the focus groups suggests that NRT should be an option 
for many research studies involving tobacco users in order to mini-
mize participant tobacco cravings and prevent breaks or disruptions in 
research flow. The provision of NRT could also serve as a modest incen-
tive for tobacco users to participate in research and public engagement 
activities. Future research should investigate this possibility as well as 
it’s possible impact on interest in quitting. In our subsequent studies, we 
will give more detailed instructions for the use of NRT, place the NRT 
so that participants are able to utilize it without drawing attention, and 
provide regular gum or candy alongside the NRT. Providing NRT is a 
helpful strategy to engage current tobacco users in a research setting.
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